Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 2
1952 2
1956 1
1957 1
1958 1
1960 2
1961 5
1962 4
1963 4
1964 7
1965 16
1966 8
1967 9
1968 6
1969 3
1970 6
1971 6
1972 2
1973 8
1974 8
1975 10
1976 4
1977 4
1978 3
1979 2
1980 1
1981 3
1982 2
1983 6
1984 5
1985 14
1986 8
1987 8
1988 9
1989 19
1990 15
1991 31
1992 26
1993 17
1994 11
1995 6
1996 13
1997 9
1998 23
1999 12
2000 17
2001 24
2002 19
2003 32
2004 28
2005 36
2006 21
2007 39
2008 42
2009 29
2010 34
2011 33
2012 38
2013 58
2014 50
2015 59
2016 49
2017 56
2018 60
2019 84
2020 83
2021 106
2022 79
2023 78
2024 64
2025 73

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,511 results

Results by year

Filters applied: . Clear all
Page 1
Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.
Quintanilla-Martinez L, Laurent C, Soma L, Ng SB, Climent F, Ondrejka SL, Zamo A, Wotherspoon A, de Leval L, Dirnhofer S, Leoncini L. Quintanilla-Martinez L, et al. Among authors: laurent c. Virchows Arch. 2023 Sep;483(3):281-298. doi: 10.1007/s00428-023-03590-x. Epub 2023 Aug 9. Virchows Arch. 2023. PMID: 37555980 Free PMC article. Review.
Carcinogenicity.
Maurici D, Aardema M, Corvi R, Kleber M, Krul C, Laurent C, Loprieno N, Pasanen M, Pfuhler S, Phillips B, Prentice D, Sabbioni E, Sanner T, Vanparys P. Maurici D, et al. Among authors: laurent c. Altern Lab Anim. 2005 Jul;33 Suppl 1:177-82. doi: 10.1177/026119290503301s16. Altern Lab Anim. 2005. PMID: 16194148 No abstract available.
Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, Gastinne T, Feugier P, Duléry R, Thieblemont C, Joris M, Jardin F, Choquet S, Casasnovas O, Brisou G, Cheminant M, Bay JO, Gutierrez FL, Menard C, Tarte K, Delfau MH, Portugues C, Itti E, Palard-Novello X, Blanc-Durand P, Al Tabaa Y, Bailly C, Laurent C, Lemonnier F. Houot R, et al. Among authors: laurent c. Nat Med. 2023 Oct;29(10):2593-2601. doi: 10.1038/s41591-023-02572-5. Epub 2023 Sep 14. Nat Med. 2023. PMID: 37710005 Free PMC article. Clinical Trial.
THBS1+ myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1.
Giraud J, Chalopin D, Ramel E, Boyer T, Zouine A, Derieppe MA, Larmonier N, Adotevi O, Le Bail B, Blanc JF, Laurent C, Chiche L, Derive M, Nikolski M, Saleh M. Giraud J, et al. Among authors: laurent c. Cell Rep. 2024 Feb 27;43(2):113773. doi: 10.1016/j.celrep.2024.113773. Epub 2024 Feb 12. Cell Rep. 2024. PMID: 38350444 Free article.
[Travel memories].
Laurent C, François A, Le Roy F, Godin M, Guerrot D. Laurent C, et al. Nephrol Ther. 2015 Jul;11(4):250-1. doi: 10.1016/j.nephro.2015.02.002. Epub 2015 May 4. Nephrol Ther. 2015. PMID: 25951950 French. No abstract available.
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study.
Cartron G, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, Jardin F, Bay JO, Gros FX, Morschhauser F, Casasnovas O, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, Drieu La Rochelle L, Feugier P, Marcais A, Griolet S, Tarte K, Laurent C, Sesques P. Cartron G, et al. Among authors: laurent c. Nat Cancer. 2025 Jul;6(7):1173-1183. doi: 10.1038/s43018-025-00941-2. Epub 2025 Apr 3. Nat Cancer. 2025. PMID: 40181090 Free article. Clinical Trial.
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).
Schwarz L, Bachet JB, Meurisse A, Bouché O, Assenat E, Piessen G, Hammel P, Regenet N, Taieb J, Turrini O, Paye F, Turpin A, Souche FR, Laurent C, Kianmanesh R, Michel P, Vernerey D, Mabrut JY, Turco C, Truant S, Sa Cunha A; PANACHE01-FRENCH08-PRODIGE48 Investigators. Schwarz L, et al. Among authors: laurent c. J Clin Oncol. 2025 Jun 10;43(17):1984-1996. doi: 10.1200/JCO-24-01378. Epub 2025 Apr 4. J Clin Oncol. 2025. PMID: 40184561 Clinical Trial.
1,511 results